Description: BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used in agriculture. BioSyent Inc. distributes its products to pharmacies and hospitals. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Toronto, Canada.
Home Page: www.biosyent.com
2476 Argentia Road
Mississauga,
ON
L5N 6M1
Canada
Phone:
905 206 0013
Officers
Name | Title |
---|---|
Mr. René C. Goehrum | Chairman, CEO & Pres |
Mr. Robert J. March | VP of Fin. & CFO |
Mr. Joost van der Mark | VP of Corp. Devel. |
Ms. Neelu Atwal | Director of HR |
Mr. Alfred D'Souza | Advisor |
Exchange: PINK
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 13.1926 |
---|---|
Trailing PE: | 14.8649 |
Price-to-Book MRQ: | 2.5633 |
Price-to-Sales TTM: | 2.2727 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 0 |